Superior Attributes Push Preference for RNA Sequencing over Conventional Sequencing Techniques
RNA sequencing has been largely considered as a vital tool to dig deeper into the cell transcriptome for insights on differential gene expression. Over the past decade, the ubiquity of RNA sequencing technique has seen rapid increase, and the adoption remains higher owing to its superior performance than that of the conventional microarray-based techniques, and Sanger sequencing method. With broader coverage, and greater resolution capabilities, RNA sequencing will continue to represent a significantly large market. The dramatically increasing number of grants for research activities in the field of next-generation sequencing (NGS)-based RNA sequencing is expected to remain a solid booster to the growth of the global RNA sequencing market. Growing significance in cancer research, and agricultural research will continue to be an important factor driving market growth. As new exciting areas of application such as spatial transcriptomics, and precision medicine emerge on the horizon, adoption of RNA sequencing is projected to proliferate over the forecast period.
Expression Profiling Top Application Type in RNA Sequencing Market
Today, the advent of sequencing technology enables direct, long-read RNA sequencing. A range of innovative computational tools are also available to assist. These will further complement the progress of the RNA sequencing market. Driven by technological advances, and increasing availability, the demand for RNA sequencing platforms and consumables continues to generate a remarkable revenue in the market. Sequencing by synthesis, on the other hand, will most likely be the preferred technology among end users. The application is anticipated to remain maximum for expression profiling, which is attributable to the rising prevalence of metabolic disorders, an increasing number of cases of multiple sclerosis, as well as that of some other conditions. Gene mutations cause abnormal or inadequate protein production, it can result in one of over 7,000 distinct types of rare and genetic diseases. About 80% of the estimated 400 million people worldwide with rare diseases are caused by a faulty gene, according to Global Genes.
As expression profiling helps with understanding diagnostics, and specific treatment options for chronic disorders, high demand will prevail in the long run as well. However, although preferred over conventional sequencing methods for its high sensitivity for gene expression, high throughput sequencing, and quantifiability, the high initial capital investment remains a substantial challenge facing more ubiquitous adoption of RNA sequencing.
Interest of Cancer Research Communities in RNA Sequencing Intact
The progresses that RNA sequencing method have exhibited over the past few decades gives strong indications about its significant application potential that has be leveraged over the foreseeable future. From bulk RNA sequencing to single-molecular, single-cell, and now till the spatial transcriptome, the approach has been revealing a high-resolution picture of individual cells with utmost accuracy. While cancers have remained a constant hot topic for researchers, RNA sequencing holds an impressive potential to aid in comprehending multiple facets in terms of both research, and therapeutics. It has already been in use within the area of oncology since the past decade to obtain invaluable insights into segments like cancer evolution, analysis of differential gene expression, biomarkers, and immunotherapy. Oncology drug resistance that has been the key obstacle responsible for the failure of cancer treatment could be potentially dealt with by using RNA sequencing technique as it presents an excellent means to aid in profound understanding of the cancer drug resistance mechanism. This would be a critical step towards the development of precision medicine for cancers, adding value to the future of cancer prevention, diagnosis, and treatment.
These are some of the recent developments on a similar line.
North America Continues to Favour Greater Adoption of RNA Sequencing Techniques for R&D
While North America has been the top performer in the global RNA sequencing market, the trend will most likely continue through the forecast period owing to the rising acceptance for RNA sequencing techniques. With the region witnessing a greater number of RNA sequencing grants, and improving reimbursement coverage for diagnostics, the market will continue to flourish in long term. The firming up of the field of personalised medicine, especially in the US, will further fortify the market performance here. Remarkably growing R&D investments in addition to robust external funding will also extend support to the expansion of market. All over the globe, several governments have been granting substantial funds to genomics research in the wake of dramatically rising prevalence of cancers, as well as rare diseases, the latter mostly being genetic/inherent.
Approximately 3-10% of all hospitalisations (regardless of the patient age) are related to a rare disease, whereas 65% of rare diseases are associated with reduced lifespan. The average time to get an accurate rare disease diagnosis is between six and eight years. According to Rare Diseases International, and EURORDIS, rare diseases currently affect at any point in time 3.5% - 5.9% of the worldwide population; 72% are genetic, of which around 70% start in childhood.
Major Participants in Global RNA Sequencing Market
Some of the most prominent players contributing towards promising growth prospects of the RNA sequencing market include Agilent Technologies, Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann La-Roche AG, Merck KGaA., BGI, F. Fluidigm Corporation, Oxford Nanopore Technologies, Lexogen GmbH, Pacific Biosciences, Becton, Dickinson and Company, QIAGEN N.V., Dolomite Bio, Takara Bio Inc., PerkinElmer Inc., Eurofins Scientific, Tecan Genomics, Inc., GENEWIZ, Inc., Hamilton Company, Macrogen, and Zymo Research. QIAGEN N.V. had launched a range of novel RNA sequencing library preparation solutions for NGS in October, 2011. In June, 2017, a strategic agreement between Agilent Technologies, and Agendia was announced over the development of a version of the latter’s RNA sequencing kit for the former’s portfolio.
Key Elements Included In The Study: Global RNA Sequencing Market
Post Sale Support, Research Updates & Offerings
We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.
Under uncertainty, traditional approaches to strategic planning can be downright dangerous. True ambiguity is no basis to forecast the future – degree of risk, the magnitude of circumstances, conditions and consequences are not known or unpredictable. To avoid dangerous binary views of uncertainty; strategic posture, moves and actions through market research is the best bet.Read more